Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III Study
Open accessAbstract
Context.—Nonvalvular atrial fibrillation (AF) carries an increased risk for stroke, but absolute rates of stroke vary widely within the broad spectrum of AF patients.Objective.—To prospectively validate a risk stratification scheme identifying patients with AF with low rates of stroke when given aspirin.Design.—Prospective cohort study with mean duration of follow-up of 2.0 years, conducted between 1993 and 1997.Setting.—Outpatient clinics affiliated with academic medical centers.Patients.—Patients with AF categorized as "low risk" based on the absence of 4 prespecified thromboembolic risk factors: recent congestive heart failure or left ventricular fractional shortening of 25% or less, previous thromboembolism, systolic blood pressure greater than 160 mm Hg, or female sex at age older than 75 years.Intervention.—All participants given aspirin, 325 mg/d.Main Outcome Measures.—Ischemic stroke (considered disabling when Rankin score was II or worse 1-3 months later) and systemic embolism (primary events).Results.—Among 892 participants, the mean (SD) age was 67 (10) years, 78% were men, and histories of hypertension, diabetes, and ischemic heart disease were present in 46%, 13%, and 16%, respectively. The rate of primary events was 2.2% per year (95% confidence interval [CI], 1.6%-3.0%), of ischemic stroke was 2.0% per year (95% CI, 1.5%-2.8%), and of disabling ischemic strokes was 0.8% per year (95% CI, 0.5%-1.3%). Those with a history of hypertension had a higher rate of primary events (3.6% per year) than those with no history of hypertension (1.1% per year) (P<.001). The rate of disabling ischemic stroke was low in those with and without a history of hypertension (1.4% per year and 0.5% per year, respectively). The rate of major bleeding during aspirin therapy was 0.5% per year.Conclusion.—Patients with AF who have relatively low rates of ischemic stroke, particularly disabling stroke, during treatment with aspirin can be reliably identified.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Simple, clinically applicable stroke risk-stratification schemes in AF patients were developed in the late 1990s in small cohort studies and later refined and validated in larger populations.
“Simple, clinically applicable stroke risk-stratification schemes in AF patients were developed in the late 1990s in small cohort studies and have later been refined and validated in larger populations.[364][365][366][367][368]”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [364]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 10 · Cited by 315
Research works printed but not linked: 16
- Atrial Fibrillation Investigators. The efficacy of aspirin in patients with atrial fibrillation: analysis of pooled data from three randomized trials. Arch In- tern Med. 1997;157:1237-1240.
- Stroke Prevention in Atrial Fibrillation Investi- gators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Pre- vention in Atrial Fibrillation II Study. Lancet. 1994; 343:687-691.
- Kopecky SL, Gersh BJ, McGoon MD, et al. The natural history of lone atrial fibrillation: a popula- tion-based study over 3 decades. N Engl J Med. 1987;317:669-674.
- European Atrial Fibrillation Trial Study Group. Secondary prevention in nonrheumatic atrial fibril- lation after transient ischemic attack or minor stroke. Lancet. 1993;342:1255-1262.
- Stroke Prevention in Atrial Fibrillation Investi- gators. Predictors of thromboembolism in atrial fi- brillation, I: clinical features in patients at risk. Ann Intern Med. 1992;116:1-5.
- Stroke Prevention in Atrial Fibrillation Investi- gators. Predictors of thromboembolism in atrial fi- brillation, II: echocardiographic features in patients at risk. Ann Intern Med. 1992;116:6-12.
- Stroke Prevention in Atrial Fibrillation Inves- tigators. Risk factors for thromboembolism during aspirin therapy in patients with atrial fibrillation: the Stroke Prevention in Atrial Fibrillation Study. J Stroke Cerebrovasc Dis. 1995;5:147-157.
- Stroke Prevention in Atrial Fibrillation In- vestigators. The Stroke Prevention in Atrial Fi- brillation III Study: rationale, design and patient features. J Stroke Cerebrovasc Dis. 1997;5:341- 353.
- Stroke Prevention in Atrial Fibrillation Inves- tigators. The Stroke Prevention in Atrial Fibrilla- tion Study: final results. Circulation. 1991;84:527- 539.
- Stroke Prevention in Atrial Fibrillation Inves- tigators. Adjusted-dose warfarin versus low-inten- sity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: the Stroke Preven- tion in Atrial Fibrillation III randomized clinical trial. Lancet. 1996;348:633-638.
- Miller VT, Rothrock JF, Pearce LA, Feinberg WM, Hart RG, Anderson DC. Ischemic stroke in patients with atrial fibrillation: effect of aspirin ac- cording to stroke mechanism. Neurology. 1993;43: 32-36.
- Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med. 1989;321:129-135.
- Lin HJ, Wolf PA, Kelly-Hays M, et al. Stroke severity in atrial fibrillation: the Framingham Study. Stroke. 1996;27:1760-1764.
- Man-Son-Hing M, Laupacis A, O'Connor A, Wells G. Warfarin for atrial fibrillation: the patient perspective. Arch Intern Med. 1996;156:1841-1848.
- Flegel KM, Hutchinson TA, Gromme PA, Tousignant P. Factors relevant to preventing em- bolic stroke in patients with nonrheumatic atrial fi- brillation. J Clin Epidemiol. 1991;44:551-560.
- Stroke Prevention in Atrial Fibrillation Inves- tigators. Bleeding during antithrombotic therapy in patients with atrial fibrillation: the Stroke Preven- tion in Atrial Fibrillation Study. Arch Intern Med. 1996;156:409-416.
- Authors
- The SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators
- Corresponding author
- The SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators
- Venue
- JAMA: The Journal of the American Medical Association
- Publisher
- American Medical Association (AMA)
- Published
- 1998-04-22
- Volume
- 279
- Issue
- 16
- Pages
- 1273-1277
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- 1538-3598
- OpenAlex
- W4254580080
- Cited by
- 315
- References
- 10
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 2 · 2023: 3 · 2022: 3 · 2021: 2 · 2020: 1 · 2019: 3 · 2018: 7 · 2017: 14 · 2016: 9 · 2015: 17 · 2014: 7 · 2013: 8 · 2012: 15
- FWCI
- 20.01
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JAMA (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Health Sciences › Medicine › Epidemiology › Acute Ischemic Stroke Management
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Keywords
- non-valvular atrial fibrillation, aspirin, stroke prevention, ischemic stroke, systemic embolism, stroke risk stratification, thromboembolic risk factors, hypertension, major bleeding, disabling stroke
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
